Epsitron

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Epsitron

What is Epsitron?

Epsitron is a pharmaceutical medication classified as a selective serotonin 5-HT3 receptor antagonist. It is primarily utilized in clinical settings to manage and prevent nausea and vomiting associated with specific medical triggers, most notably systemic cancer treatments and surgical procedures.

Mechanism of Action

The active component in Epsitron works by blocking the action of serotonin, a natural substance in the body that can trigger the vomiting reflex. During chemotherapy, radiation, or surgery, the body may release an excess of serotonin, which binds to 5-HT3 receptors located on the vagus nerve and in the chemoreceptor trigger zone of the brain. By binding to these receptors instead of serotonin, Epsitron helps interrupt the signals that lead to the sensation of nausea and the physical act of vomiting.

Clinical Applications

Epsitron is typically integrated into care plans for the following indications:

  • Chemotherapy-Induced Nausea and Vomiting (CINV): Used to prevent symptoms occurring both shortly after treatment and during the subsequent recovery period.
  • Radiation-Induced Nausea and Vomiting (RINV): Administered to patients undergoing total body irradiation or localized abdominal radiation.
  • Postoperative Nausea and Vomiting (PONV): Utilized in the surgical recovery phase to assist patients who are sensitive to anesthesia or the physical stress of surgery.

Therapeutic Goal

The primary objective of Epsitron therapy is to improve the quality of life for patients undergoing intensive medical interventions. By managing gastrointestinal distress, the medication helps patients maintain better nutritional intake and hydration levels throughout their treatment course.

Regulatory References

  1. ACE inhibitors: MedlinePlus Medical Encyclopedia

What side effects are possible with Epsitron?

The officially documented safety profile for Epsitron (Captopril) is organized by frequency and the body system affected, consistent with regulatory standards (e.g., EMA/FDA). This framework defines both expected reactions and serious, rare safety events.

Adverse Reaction Scope

Category Description
Frequency Classification Common effects include a dry, persistent cough, dizziness, and taste impairment (dysgeusia). Uncommon effects include hypotension and chest pain. Rare effects include serious skin reactions and intestinal angioedema. Very Rare reports document neutropenia and hepatic damage.
System-Organ Classes Adverse reactions are reported across the Vascular, Respiratory, Nervous System, Skin, Renal and Urinary, and Blood and Lymphatic systems.
Serious Adverse Reactions Officially documented serious reactions include life-threatening Angioedema of the larynx or glottis, severe Hypotension, blood disorders like Neutropenia, and acute Renal Failure, particularly in susceptible patients.
Population-Specific Notes The medication is formally contraindicated during the second and third trimesters of pregnancy due to the risk of fetal toxicity. Patients with bilateral renal artery stenosis carry a documented risk of severe renal function deterioration.
Exposure-Related Patterns Hypotension may be more likely to occur after the first dose or a dose increase. Angioedema can be reported at any time during treatment.

Regulatory Safety Structure

The safety profile includes formal contraindications against use in patients with a history of ACE inhibitor-related angioedema and during the second and third trimesters of pregnancy. These formal restrictions and the classification of effects define the regulatory boundaries for the use of Epsitron.

Overdose and Emergency Response

Overdose with Epsitron (Captopril) primarily manifests as an extension of its therapeutic effects, resulting in profound hypotension, which can progress to shock, accompanied by lethargy and bradycardia. Acute, severe outcomes documented in regulatory sources include acute renal failure and, in rare instances due to extensive blood pressure drop, cerebrovascular incidents. A critical and life-threatening complication is the potential for angioedema involving the larynx or glottis.

Immediate medical attention is required for any signs of overdose or in cases of collapse, seizure, or difficulty breathing. The official labeling mandates prompt administration of epinephrine for severe laryngeal angioedema. Additionally, individuals should contact a poison control helpline immediately.

There is no specific antidote known for Captopril overdose. Management is symptomatic and supportive. Regulatory procedures documented include placing the patient in a supine position and administering intravenous fluid replacement for hypotension. Haemodialysis is described as a means to effectively remove the drug from the circulation. Symptomatic or hypotensive patients require hospital monitoring for a minimum of 24 hours, which includes the monitoring of BUN and serum creatinine levels. Patients with renal insufficiency should be monitored for hyperkalemia.

Therapeutic Uses of Epsitron

What Epsitron treats: Main Uses and Benefits

Epsitron is applied across domains where additional symptomatic support is needed to address symptoms related to systemic imbalance and increased physiological stress. The medication may assist with managing the chronic clinical challenge of elevated systemic arterial pressure, and it is relevant for easing symptoms linked to Heart Failure marked by left ventricular dysfunction.

This application contributes to easing the overall symptom load by helping to relieve physiological strain. It is also considered relevant for long-term stabilization after an acute myocardial infarction and is applied in addressing Diabetic Nephropathy in certain patient groups.

This medication is commonly used to help with hypertension, chronic heart failure, and post-heart attack stabilization. It is applied when appropriate to manage conditions presenting with systemic or localized discomfort, which generally helps patients cope more steadily with symptom fluctuations.

Quick Fact: Applied in addressing Physiological Strain

Regulatory References

  1. NIH DailyMed Product Label

Eligibility and Restrictions for Use

The eligibility for Epsitron (Captopril) is strictly defined by regulatory authorities and centers on absolute contraindications and conditions requiring limited use.

Populations and Conditions that Must Not Use Epsitron

Epsitron is strictly contraindicated for:

  • Patients with a history of angioedema (severe swelling of the face, tongue, or throat) related to any prior ACE inhibitor therapy, or those with hereditary or idiopathic angioedema.
  • Use during the second and third trimesters of pregnancy due to the risk of fetal injury or death. It is also not recommended during the first trimester.
  • Patients with diabetes receiving concomitant treatment with aliskiren-containing products.

Restricted and Conditional Use

Use is limited and requires special medical consideration for:

  • Impaired Renal Function: Patients with significant kidney impairment are eligible only under conditional use, requiring adjustments as directed by their physician. Use is prohibited with severe impairment for certain combination products.
  • Pediatric Population: Safety and efficacy are not fully established in children and adolescents; use is generally reserved for situations where other treatments have been ineffective and must be initiated under close supervision.
  • Bilateral Renal Artery Stenosis or stenosis of the artery to a single functioning kidney, due to an increased risk of severe kidney impairment.

What should I know about interactions with other medicines?

Epsitron (Captopril, an ACE inhibitor) can interact with a number of other medications, altering its effects or increasing the risk of serious side effects. It is crucial to inform your healthcare provider about all prescription, over-the-counter drugs, and supplements you are taking.

️ Contraindicated Combinations

Aliskiren: Concomitant use with aliskiren-containing products is contraindicated in patients with diabetes mellitus or moderate-to-severe kidney impairment (GFR < 60 mL/min/1.73 m^2) due to an increased risk of hypotension, hyperkalemia, and kidney changes.

Sacubitril/Valsartan (e.g., Entresto): Co-administration with Neprilysin Inhibitors, such as sacubitril/valsartan, is contraindicated. Epsitron should not be started within 36 hours before or after switching to or from a medicine containing sacubitril/valsartan, as this significantly increases the risk of angioedema (severe swelling).


Caution with Other Medicines

Drug Class Potential Interaction & Risk
Potassium-Sparing Diuretics/Potassium Supplements Increased risk of hyperkalemia (high potassium levels in the blood).
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Reduced blood pressure-lowering effect of Epsitron and increased risk of worsening kidney function (including kidney failure) and hyperkalemia.
Lithium Epsitron can increase lithium blood levels, which may result in lithium toxicity. Serum lithium levels must be closely monitored.
Other Antihypertensives (e.g., Beta-blockers, Diuretics) May cause an additive hypotensive effect, leading to excessively low blood pressure.
mTOR Inhibitors (e.g., Everolimus, Temsirolimus) Increased risk of angioedema.

Mechanism of Action

Epsitron exerts its core effect through a dual mechanism, primarily involving the modulation of cerebral blood flow pathways and the initiation of neuroprotective cascades by modulating key enzyme and ion channel systems.

Increasing Cerebral Blood Flow via Enzyme Inhibition

Epsitron acts as a selective inhibitor of the enzyme calcium-calmodulin-dependent cyclic GMP-specific phosphodiesterase ( CaM- cGMP-PDE), particularly in the cerebral vasculature. This inhibition leads to a rise in the intracellular signaling molecule cGMP. The resulting accumulation of cGMP triggers vasodilation (widening) of cerebral blood vessels, thereby selectively enhancing cerebral blood flow ( CBF) and increasing oxygen supply to brain tissue.

Direct Neuroprotection Through Ion Channel Modulation

A parallel effect involves the drug's role in the ion channel modulation domain. Epsitron suppresses excessive electrical activity by inhibiting neuronal voltage-dependent sodium ( Na^+) channels on nerve cell membranes. This action reduces the influx of Na^+ ions, leading to a reduction in neuronal excitability and initiating a neuroprotective cascade against cellular overstimulation.

Dosage and Administration Information

Epsitron, which contains the active ingredient Captopril, is administered orally as a tablet or, in some regions, as an oral solution. The official dosing guidelines require a multiple daily frequency of two to three times per day (BID or TID) due to the drug’s short half-life.

Administration Timing and Dosing Protocol

The tablet form must be taken on an empty stomach, generally one hour before a meal, because food significantly reduces the amount of medicine absorbed. For conditions such as hypertension, the initial adult dose is typically 25 mg two or three times daily, with a gradual titration (increase) every one to two weeks. For heart failure, the starting dose is lower, ranging from 6.25 mg to 12.5 mg TID. The maximum daily dose for most adults is 450 mg in certain clinical regions, while other regional guidelines specify a maximum of 150 mg.

Special Conditions and Dose Adjustments:

Treatment initiation for severe conditions like heart failure and post-myocardial infarction often requires close medical supervision. The dosage must be reduced and/or the dosing interval prolonged for patients with confirmed renal impairment. Older adults may also require a lower starting dose (e.g., 6.25 mg BID). If a dose is missed, standard practice is to skip the missed dose and return to the regular schedule if it is almost time for the next one, never taking two doses at once.

Recent Clinical Evidence

Research evidence / Overview of studies for Epsitron (Captopril)

This section provides a factual overview of the types of research and clinical trials that have investigated Epsitron (Captopril), focusing only on the structure of the evidence and what the studies observed, while strictly avoiding clinical advice or guaranteed results.


Evidence for Use in Hypertension (Elevated Systemic Arterial Pressure)

The foundation of the evidence for Epsitron in managing elevated systemic arterial pressure was examined through research, primarily through Randomized Controlled Trials (RCTs) and large-scale meta-analyses that compared outcomes against placebo or other established treatments. These studies were conducted in a broad population of adults with primary hypertension.

Research examined both the short-term outcomes related to changes in systolic and diastolic blood pressure (BP) measurements and the long-term tracking of major cardiovascular outcomes. Findings from the studies report measured changes in blood pressure that were lower and, over extended follow-up periods, described patterns of variability in recorded cardiovascular event rates between groups.


Evidence for Use in Chronic Heart Failure

The use of Epsitron in chronic heart failure is supported by key large-scale, long-term RCTs that specifically enrolled adults diagnosed with moderate to severe heart failure. Research examined multiple outcomes, including the frequency of hospitalization due to heart failure, outcomes related to overall survival, and changes in functional capacity. Studies report how symptoms evolved in the observed populations, describing patterns of variability in hospitalization rates and differences in outcomes related to overall survival between the Captopril groups and control groups over follow-up durations extending for years.

What remains uncertain: Evidence for its use was derived largely from studies focused on patients with a reduced ejection fraction. There is limited information for outcomes in patients with Heart Failure with preserved Ejection Fraction (HFpEF).


Evidence for Use Following Myocardial Infarction (MI)

The evidence for Epsitron following a heart attack is derived from a major randomized, placebo-controlled trial that specifically enrolled patients who had survived the acute event but had documented left ventricular dysfunction. The core trial tracked the occurrence of recurrent myocardial infarction and the prevention of progression to overt heart failure over multiple years. Studies described patterns where differences in outcomes related to overall survival and cardiovascular death rates were observed, alongside a variability in the rate of developing overt heart failure compared to the placebo group.

Key Studies & References

  1. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.
  2. A placebo-controlled trial of captopril in refractory chronic congestive heart failure. Captopril Multicenter Research Group.

Frequently Asked Questions (FAQ)

Common questions about Epsitron (FAQ)


Q: What is the main difference between Epsitron and other medicines used for the same condition?

A: Official information notes that Epsitron is classified as an ACE inhibitor. It is structurally unique within this class because it contains a sulfhydryl group. This chemical feature differentiates it from many other similar medicines that are administered as prodrugs, which require the body to convert them into the active form.

Q: Do people take Epsitron long-term?

A: Studies and official documents indicate that Epsitron is used in the long-term management of certain chronic conditions, such as hypertension and heart failure. Clinical research has examined its effects and safety profile over extended follow-up periods spanning multiple years.

Q: Is it normal to feel a change within the first week of starting Epsitron?

A: It is noted in regulatory information that effects related to low blood pressure (hypotension) may be more likely early in treatment, such as after the very first dose or when the dose is increased. This change may be experienced as a feeling of dizziness or lightheadedness.

Q: Is Epsitron safe to use if I have a history of liver problems?

A: Regulatory documents state that Epsitron should be used with caution if an individual has a history of liver disease. This is because the condition may be made worse by the medicine, and use typically involves close medical monitoring.

Q: Does Epsitron affect my ability to drive or operate machinery?

A: Because Epsitron may cause side effects like dizziness or lightheadedness related to low blood pressure, official product information advises caution. Regulatory warnings indicate that driving or operating heavy equipment should be avoided until an individual knows how the medicine affects their ability to safely perform these tasks.

Q: Does Epsitron cause weight gain?

A: Weight gain or swelling is a symptom commonly associated with conditions like heart failure, which Epsitron is used to treat. According to the official product information, weight gain is not listed as one of the common or frequent side effects of the medicine itself.

Q: Is Epsitron a controlled substance?

A: Official regulatory classification under the Controlled Substances Act (CSA) states that Epsitron is not a controlled drug. It is, however, only available by prescription from a licensed healthcare provider.

Q: Can Epsitron be crushed or split?

A: Crushing or splitting the tablet is not generally recommended in official guidelines. If a patient has difficulty swallowing the tablet form, a licensed alternative formulation, such as an oral solution, may be available for use.

Q: Why do some users feel tired when they first start Epsitron?

A: Excessive tiredness or fatigue is a side effect that has been reported in clinical experience with Epsitron. This feeling may also be related to the initial effects of the medicine on blood pressure, such as a drop in blood pressure, which can cause fatigue.

Q: How does the body get rid of Epsitron?

A: According to official pharmacokinetic information, Epsitron is primarily removed from the body through the kidneys in a process called renal excretion. A smaller portion of the medicine is processed (metabolized) by the liver.

Q: Can men and women take Epsitron for the same reasons?

A: The approved uses for Epsitron, such as for hypertension and heart failure, apply to both men and women in the adult population. However, it is important to note that the medicine is formally contraindicated (must not be used) during the second and third trimesters of pregnancy due to documented risks to the fetus.

Q: Is Epsitron known to cause any long-term health problems?

A: Studies of Epsitron spanning multiple years indicate that side effects seen early in treatment did not become a problem during prolonged use. Furthermore, official research found no evidence of drug tolerance, meaning the medicine continued to work effectively over time.

Q: Are the side effects of Epsitron temporary?

A: Some common side effects are noted as resolving after the medicine is stopped. According to long-term study data, some side effects experienced early in therapy, such as rash or taste disturbance, were observed to potentially lessen over the course of prolonged use.

Q: Are there any specific foods or drinks to avoid while taking Epsitron?

A: Regulatory warnings indicate that patients should avoid moderately high or high potassium dietary intake. This is because Epsitron can increase potassium levels in the blood (hyperkalemia). Official guidance usually recommends against the use of salt substitutes or potassium supplements, unless specifically directed by a healthcare provider.

Q: Are there any known issues with taking Epsitron before surgery?

A: Medical guidelines often state that ACE inhibitors like Epsitron are typically continued until the day before a planned surgery. They are commonly recommended to be discontinued on the day of the procedure itself to help manage the risk of low blood pressure during the surgery.

Q: Can I drink alcohol while taking Epsitron?

A: Official product information states that alcohol may have an additive effect with Epsitron in lowering blood pressure. This combination can increase the risk of experiencing symptoms such as lightheadedness, dizziness, or fainting.

Q: Does the efficacy of Epsitron decrease over time?

A: Regulatory-referenced studies indicate that patients did not develop drug tolerance over time. This suggests that the medicine's ability to maintain blood pressure control and its overall efficacy does not decrease significantly during prolonged use.

Q: How long does the effect of one dose of Epsitron typically last?

A: Official pharmacokinetic data describes the duration of action for one dose as typically lasting between 12 to 24 hours. This time frame is based on average data and may vary.

Q: What kind of monitoring is needed when a patient is on Epsitron?

A: According to official precautions, healthcare providers commonly check patient progress at regular visits as a standard part of treatment. Blood and urine tests are typically part of this monitoring to check for unwanted effects, especially concerning kidney function and changes in blood potassium levels.

Q: Why do some people stop taking Epsitron?

A: Clinical studies report that reasons for discontinuation included experiencing side effects such as rash or taste disturbances, and in some cases, a failure to maintain adequate blood pressure reduction over time.

Q: Does Epsitron cause dependence?

A: Official classification under the Controlled Substances Act states that Epsitron is not a controlled drug. This classification indicates that the medicine has no known potential for abuse or dependence.

Q: Is there a link between Epsitron and mental health changes?

A: The official safety profile includes adverse reactions within the Nervous System class. However, specific mental health changes such as depression or anxiety are not listed as common or frequent adverse reactions associated with the medicine.

Q: Is Epsitron approved in countries outside the US?

A: Yes, official documents confirm that Epsitron (Captopril) has received approval from multiple international regulatory bodies. These include the FDA (US), European authorities, and the Japanese authorities (PMDA/MHLW).

Q: Can people with diabetes use Epsitron?

A: Yes, Epsitron is specifically indicated for use in managing diabetic nephropathy (a type of kidney disease) in patients who have type I insulin-dependent diabetes. However, the medicine carries a specific contraindication for use in individuals with diabetes who are concurrently taking a medicine containing aliskiren.

How should Epsitron be stored and disposed of?

Epsitron (Captopril) must be stored strictly according to regulatory mandates to maintain its stability and effectiveness. The medication requires storage at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F). Protection from moisture is mandatory; therefore, the tablets must be kept in a tightly closed container.

For safety, the medication must be stored out of the reach and sight of children. Disposal of unused or expired Epsitron should follow official pharmaceutical waste guidelines, prioritizing the use of a drug take-back program. Disposal in household trash is permissible only if mixed with an undesirable substance and sealed; the product must not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Epsitron found in:

A-Z Index: